SUVEN LIFE SCIENCES LTD is a Healthcare Services company listed on NSE. The annual-report business brief for this company has not been generated yet; the numbers below are as filed.
| ₹ crore · consolidated | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Revenue | 12 | 14 | 12 | 7 | 7 |
| EBITDA (ex other income) | (122) | (120) | (121) | (166) | (285) |
| margin % | (1033.3) | (885.5) | (1031.0) | (2490.7) | (3998.8) |
| Owners' profit | 0 | 0 | (105) | (161) | (276) |
| EPS, as reported (₹) | (9.57) | (6.63) | (4.82) | (7.37) | (12.13) |
| ROE % · ROCE % | (126.9) · (121.8) | (31.5) · (31.2) | (38.9) · (39.0) | (146.1) · (143.9) | (46.7) · (46.5) |
| Debt / equity (x) | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash from operations | (128) | (208) | (83) | (154) | (302) |
| Capex | (20) | (3) | (2) | (37) | (5) |
| ₹ crore | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 3 | 2 | 1 | 2 | 1 | 3 | 2 | 4 |
| Profit before tax | (50) | (39) | (44) | (52) | (77) | (102) | (46) | (128) |
| Net profit | (50) | (39) | (44) | (52) | (77) | (102) | (46) | (128) |
| EPS (₹) | (2.27) | (1.79) | (2.02) | (2.36) | (3.48) | (4.55) | (2.02) | (4.84) |
| Company | M.cap ₹ cr | P/E | P/B | EV/EBITDA | ROE % | ROCE % | Rev CAGR 5y % | EBITDA m. % |
|---|---|---|---|---|---|---|---|---|
| SYNGENE INTERNATIONAL LTD | 15,466 | 69.7 | 3.20 | 16.7 | 6.5 | 7.5 | 11.3 | 13.9 |
| INDEGENE LIMITED | 13,959 | 34.7 | 4.45 | 20.4 | 12.8 | 14.9 | — | 19.1 |
| SUVEN LIFE SCIENCES LTD ◆ | 9,476 | — | 16.02 | — | (46.7) | (46.6) | (12.0) | (3504.9) |
| VIMTA LABS LIMITED | 2,819 | 22.8 | 8.22 | 31.1 | 8.0 | 11.0 |
| Date · filing | Category | Importance | 1-day % | 5-day % |
|---|---|---|---|---|
| 3 Sept 2026 · Suven Life Sciences Completes Phase-3 Patient Enrollment for Masupirdine Study | business updates | high | — | — |
| 25 Aug 2026 · 37th AGM held; all 5 resolutions passed with requisite majority | board shareholder meetings | low | — | — |
| 25 Aug 2026 · 37th AGM held on Aug 25 2026 - all 5 resolutions passed | board shareholder meetings | low | — | — |
| 11 Aug 2026 · Crisil Monitoring Agency Report for Q1 FY27 on Preferential Issue proceeds | fund raising | medium | — | — |
| 7 Aug 2026 · Suven Life Sciences publishes Q1 FY27 unaudited results in newspapers | compliance | minimal | — | — |
| 6 Aug 2026 · Suven Life Sciences Q1 FY27 results: consolidated net loss widens to about Rs 127.61 cr | results | high | — | — |
| 31 Jul 2026 · Suven Life Sciences announces 37th AGM on 25 Aug 2026, e-voting details | compliance | minimal | — | — |
| 30 Jul 2026 · Board meeting on Aug 6, 2026 to consider Q1FY27 results | results | low | — | — |
| 30 Jul 2026 · Letter to shareholders on FY26 Annual Report web link | compliance | low | — | — |
| 30 Jul 2026 · Suven Life Sciences files BRSR for FY 2025-26 | compliance | low | — | — |
| Where a broker report shows | This document shows | Why |
|---|---|---|
| A rating (BUY / ADD / REDUCE / SELL) | A state: the latest filed quarter and the measured reactions |
| 8.4 |
| 38.2 |
| TAKE LIMITED | 261 | 20.5 | 8.40 | 54.5 | 35.0 | 14.2 | (41.2) | 3.5 |
| BILCARE LTD. | 219 | 6.2 | 2.95 | 11.8 | (23.3) | (3.9) | 3.3 | 15.7 |
| Metric | Company | Group median | Rank | Better than |
|---|---|---|---|---|
| P/B | 16.0 | 5.2 | 55 of 57 | 4% |
| ROCE | (46.6) | 8.0 | 66 of 69 | 4% |
| ROE | (46.7) | 9.4 | 57 of 59 | 3% |
| Debt / Equity | 0.0 | 0.1 | 3 of 59 | 76% |
| EBITDA margin | (3504.9) | 21.5 | 56 of 57 | 2% |
| Revenue growth | 91.0 | 20.2 | 5 of 57 | 93% |
| Profit growth | (147.7) | 11.4 | 52 of 55 | 6% |
| Market cap | 9476 | 261 | 17 of 71 | 77% |
| an event is a fact; a rating is an opinion that requires SEBI RA registration |
| A target price and upside | The current price and the multiples against the group | a target is a forecast; a multiple is a measurement |
| Estimate years marked E | More audited years; no estimates | MarketPing publishes no forecasts — your own model lives on the Models page |
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.
